arrow
F

Francesca Zacchi

Vall d'Hebron Barcelona Hospital Campus
H指数:7
被引数:204

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial

Talazoparib联合恩扎卢胺治疗高负荷转移性激素未治前列腺癌:一项随机Ⅱ期试验

2026-10-140
OAAI
Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors

白细胞介素-8:一种整合癌症生物学和宿主反应的泛肿瘤生物标志物

2026-04-140
PRE
Interleukin-8 as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis

白细胞介素-8作为肾细胞癌潜在预后生物标志物:一项系统评价和荟萃分析

2025-09-010
OAAI
Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study

转移性激素敏感性前列腺癌患者接受雄激素剥夺+恩扎卢amide±唑来膦酸治疗后的全身及区域性体成分变化。BONENZA研究

2025-06-010
OAAI
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial

唑来膦酸联合恩扎鲁他胺和雄激素剥夺治疗转移性激素敏感性前列腺癌: 随机II期BONENZA试验

2025-05-030
PRE
Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
2025-02-210
OAAI
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study

阿帕卢他胺在转移性去势敏感前列腺癌中的应用:多中心真实世界ARON-3研究的结果

2024-11-010
OAAI
Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation plus enzalutamide plus /- zoledronic acid: The BonEnza study

转移性激素敏感性前列腺癌(mHSPC)患者接受雄激素剥夺联合恩扎卢胺联合/不联合唑来膦酸治疗后的全身及区域身体成分变化:BonEnza研究

2024-09-010
PRE
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide
2024-09-012
OA
Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial

全身磁共振成像作为去势抵抗性前列腺癌骨转移的治疗反应生物标志物: iPROMET临床试验

2024-09-016
PRE